Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Biofinderon Jul 25, 2018 3:51pm
328 Views
Post# 28366839

IPF: The opportunity for Prometic’s PBI-4050

IPF: The opportunity for Prometic’s PBI-4050The numbers affected:
• 140,000 people in the U.S. diagnosed with IPF 64% are mild to moderate
 
The limitations of other drugs:
Current issues with existing products include:
• Slow pulmonary function loss
• Modest effect on slowing disease progression
• No demonstration of reversal
• Require management of side effects
 
The revenues generated:
Sales forecast in 2020 are expected to exceed $3bn
 
Prometic’s opportunity:
Approximately 60,000 patients with mild to moderate IPF are not being treated by Esbriet or Ofev. This creates a huge opportunity for PBI-4050.
 
Prometic’s opportunity:
PBI-4050 has demonstrated superior safety, tolerability and efficacy results to existing products on the market. PBI-4050 reverses fibrosis in six organs: lungs, kidneys, heart, pancreas, liver, and skin.
 
Bullboard Posts